describe two patients with advanced gastric cancer in whom interstitial pneumonitis developed after several courses of a chemotherapy regimen based on weekly PTX administration.
, for 1 h. Premedication with dexamethasone (8 mg), ranitidine (50 mg), and diphenhydramine (50 mg) was administered prior to the administration of PTX. The chemotherapy courses were repeated every 3 weeks. A computed tomography (CT) scan before chemotherapy with PTX was started showed minimal consolidative changes and subpleural lines in the bilateral lower lung fields (Fig. 1A) . After 8 administrations of PTX, a CT scan was performed to detect lung metastasis. Minimal consolidative areas were observed, and the subpleural lines showed slight exacerbation (Fig. 1B) . A CT scan of the abdomen showed the size of the lymph node metastasis was stable. After 10 administrations of PTX, he developed a transient cough and a low-grade fever, which resolved spontaneously in 2 days. Four days after 11 administrations of PTX, he developed a nonproductive cough and progressive dyspnea. Physical examination revealed
Introduction
Paclitaxel (PTX) (Taxol; Bristol-Myers Oncology, Princeton, NJ, USA) is a chemotherapeutic agent widely used in the management of a range of malignant disorders, including carcinoma of the lung, breast, and ovary, and gastric cancer. Common PTX toxicities include neutropenia, neuropathy, and hypersensitivity reactions [1] . Pulmonary toxicity related to the administration of PTX is a rare event, but can be fatal [2] . We Offprint requests to: K. Shitara Received: March 30, 2006 / Accepted: June 5, 2006 fine crackles in the bilateral lungs. Arterial blood gas analysis was as follows: pH, 7.49; PCO 2 , 31.2 mmHg; and PO 2 , 45.4 mmHg. Laboratory values were as follows: white blood cell count, 8100/ml (neutrocytes, 84%); Creactive protein, 10.4 mg/dl; lactate dehydrogenase (LDH), 724 IU/ml; and sialylated carbohydrate antigen KL-6 (KL-6), 2610 U/ml. A CT scan showed extensive bilateral areas of ground-glass attenuation, especially in peripheral regions (Fig. 1C) . Cultures of sputum and blood were negative for infection. b-d-Glucan was within the normal range. Drug-induced lymphocyte stimulation test (DLST) for PTX was negative. Druginduced interstitial pneumonitis related to PTX was suspected on the basis of the clinical course and findings. High-dose steroid therapy (IV methylprednisolone 1 g daily for 3 days; IV prednisolone 50 mg daily for the next 4 days) was given, but it was ineffective. He developed respiratory failure requiring tracheal intubation and mechanical ventilation, and a tracheotomy was performed. A total of four cycles of high-dose steroid and two cycles of cyclophosphamide were given, but all were ineffective. A CT scan obtained 1 month after the diagnosis of pneumonitis showed further exacerbated ground-glass attenuation and consolidative changes in the bilateral lungs (Fig. 1D ). He died 57 days after the last PTX administration.
Case 2
A 61-year-old man with a history of myocardial infarction at the age of 50 years and a 20-pack-a-year history of cigarette smoking was diagnosed with gastric cancer at Kameda Medical Center in June 2004. A CT scan before chemotherapy was begun showed a 94 ¥ 80-mm metastatic tumor in the left lobe of the liver ( Fig. 2A) .
Combination therapy of S-1 and cisplatin was begun. S-1 was given consecutively, at 80 mg/m 2 , on days 1 to 21. Cisplatin was given at 60 mg/m 2 on day 8. The treatment was repeated every 5 weeks. After two courses of this treatment, the liver metastasis remained stable (Fig.  2B ), but the gastric tumor had become enlarged, so weekly PTX chemotherapy was started as second-line treatment. PTX was given at 80 mg/m 2 on days 1, 8, and 15. This treatment was repeated every 3 weeks. Premedication was similar to that in case 1. A CT scan before PTX chemotherapy showed slight consolidative changes and subpleural lines (Fig. 3A) , but the patient noticed no symptoms. After four administrations of PTX, the dose of paclitaxel was reduced to 70 mg/m 2 , due to the occurrence of grade 3 febrile neutropenia. After six administrations, the liver metastasis was reduced in size (38 mm; 59% reduction; Fig. 2C ), and after 20 administrations, the liver metastasis was further reduced in size (Fig. 2D) . Two days after 21 administrations of PTX, he was hospitalized with fever, nonproductive cough, and progressive dyspnea. A CT scan showed extensive bilateral areas of ground-glass attenuation with honeycomb changes (Fig. 3B,C) . Arterial blood gas analysis was as follows: pH, 7.42; PCO 2 , 35 mmHg; and PO 2 , 62 mmHg. Laboratory values were as follows: white blood cell count, 4400/ml (neutrocytes, 70%); C-reactive protein, 8.85 mg/dl; LDH, 942 IU/ml; and KL-6, 4340 U/ml. Cultures of sputum and blood were negative for infection. DLST for PTX was negative. High-dose steroid therapy, cyclophosphamide, and cyclosporine were given, but all were ineffective. He died 50 days after the last PTX administration. 
Discussion
The principal mechanism of action of PTX is the induction of stable polymerization of microtubules by the inhibition of microtubule disassembly. Because microtubules are essential for cell division, cells exposed to PTX are arrested in the premitotic G2 phase and fail to divide [1] . Three complications have been reported with PTX-induced pneumonitis: allergic reaction [3] , type IV hypersensitive reaction [4] , and cytotoxicity [5] . Stable polymerization of microtubules causes macrophages to release tumor necrosis factor (TNF)-a and interleukin (IL)-1, which have an antitumor effect [6] . However, these cytokines may have a cytotoxic effect on normal lung cells, and fibrosis may occur during the healing process [5] . This mechanism was suggested by an autopsy that showed marked fibrosis around shrunken metastatic tumors of the lung and liver [5] . The prevalence of grade 3 or more severe interstitial pneumonitis was shown to be approximately 0.73% (23/3169 cases) in a clinical trial in Japan that progressed until December 2002 [2] . Interstitial pneumonitis was more frequently reported with weekly or biweekly administration (1.41%) than with tri-weekly administration (0.27%) [2] . We experienced 2 cases of pneumonitis among 210 patients treated with PTX at Kameda Medical Hospital and 62 patients treated with PTX at Misawa City Hospital, putting its frequency at approximately 0.73% (2/272). It was also reported that pneumonitis occurred more rapidly with weekly regimens than with tri-weekly regimens [7] . In post-marketing research in Japan, 20 cases of pneumonitis were reported in gastric cancer patients receiving PTX, with 13 recoveries [8] . The 7 patients who did not recover had been treated weekly with PTX monotherapy, receiving no combination therapy. No difference in the total dose of PTX was observed between those who died and those who recovered, so it seems that complications may develop at any time [8] . Some studies have reported that those undergoing combination therapies with taxanes and other agents, such as gemcitabine, had a higher risk of pneumonitis [9] . Similarly, pneumonitis was also reported in patients treated with docetaxel [10] . Our two patients had minimal consolidative changes in their lungs before treatment, and the presence of these charges may be one of the risk factors for pneumonitis. In addition, a long history of cigarette smoking may play a role in the development of PTX- induced pneumonitis, because smoking itself is recognized as one of the risk factors for interstitial pneumonitis or idiopathic pulmonary fibrosis [11] . It is important to consider symptoms such as cough and low-grade fever during treatment with PTX, as potential indicators of the possibility of onset of pneumonitis. PTX-induced pneumonitis needs to be considered in the differential diagnosis when patients treated with PTX present with respiratory symptoms. Infection must be ruled out, and a steroid should be administered during the early stages, because there are some case reports that early administration of steroids was effective for the treatment of drug-induced pneumonitis [12] .
